Article Details

Leo Pharma's FDA nod adds a challenger to Dupixent's dominance in eczema - MedCity News

Retrieved on: 2021-12-28 17:18:49

Tags for this article:

Click the tags to see associated articles and topics

Leo Pharma's FDA nod adds a challenger to Dupixent's dominance in eczema - MedCity News. View article details on hiswai:

Excerpt

AstraZeneca kept rights to the drug for other indications outside of skin diseases, including a then ongoing program in asthma. However, AstraZeneca ...

Article found on: medcitynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up